Anti-interleukin-5 therapy in patients with severe asthma: from clinical trials to clinical practice

被引：1
|
作者：
Beasley, Richard [1 ,2 ]
Harper, James [1 ]
Masoli, Matthew [3 ]
机构：
[1] Med Res Inst New Zealand, Wellington 6242, New Zealand
[2] Capital & Coast Dist Hlth Board, Wellington, New Zealand
[3] Univ Exeter, Royal Devon & Exeter Hosp, Exeter, Devon, England
来源：
LANCET RESPIRATORY MEDICINE | 2020年 / 8卷 / 05期
关键词：
BENRALIZUMAB; ANTIBODY; SAFETY;
D O I：
10.1016/S2213-2600(20)30051-5
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：425 / 427
页数：4
相关论文
共 50 条
  • [41] Anti-interleukin-5 therapy (mepolizumab) in life-threatening asthma attack: A case-based discussion
    Tello, Khodr
    Hoffmann, Andreas
    Beutel, Bjoern
    Greulich, Timm
    Vogelmeier, Claus Franz
    Richter, Manuel Jonas
    Kuhnert, Stefan
    Boeselt, Tobias
    Alter, Peter
    Holland, Angelique
    Idzko, Marco
    Buhl, Roland
    Koczulla, Andreas Rembert
    RESPIRATORY MEDICINE CASE REPORTS, 2019, 28
  • [42] Efficacy and safety of anti-interleukin-5 therapy in patients with chronic obstructive pulmonary disease: A meta-analysis of randomized, controlled trials
    Lan, Shao-Huan
    Lai, Chih-Cheng
    Chang, Shen-Peng
    Hsu, Chun-Chun
    Chen, Cheng-Hsin
    Wang, Ya-Hui
    Huang, Yueh Lan
    Wang, Cheng-Yi
    Lin, You-Shuei
    JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2022, 55 (01) : 26 - 35
  • [43] Cumulative corticosteroid-sparing effect of anti-interleukin-5/5Ra in eosinophilic asthma
    Kroes, Johannes A.
    Zielhuis, Sybrand W. J.
    De Jong, Kim
    Hashimoto, Simone
    Sont, Jacob K.
    Zielhuis, Sander W.
    Roon, Eric N. Van
    Bel, Elisabeth H.
    Ten Brinke, Anneke
    RAPSODI Team
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60 (05)
  • [44] Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma
    Hilvering, Bart
    Xue, Luzheng
    Pavord, Ian D.
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2015, 9 (04) : 135 - 145
  • [45] Phenotypes of severe asthma in clinical practice
    Lacwik, Piotr
    Kupczyk, Maciej
    Kuna, Piotr
    ALERGIA ASTMA IMMUNOLOGIA, 2013, 18 (02): : 71 - 76
  • [46] Omalizumab for severe asthma in clinical practice
    Vilja, J.
    Viinanen, A.
    ALLERGY, 2017, 72 : 559 - 559
  • [47] Clinical Predictors of Treatment Failure to Anti-IL5 Therapy in Severe Eosinophilic Asthma
    Reihman, A. E.
    Liu, C.
    Cruse, M. H.
    Freid, L.
    Perez, N.
    Smith, V. L.
    Ferguson, L.
    Wechsler, M.
    Holguin, F.
    Manka, L.
    Sharma, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [48] NOVEL USE OF ANTI-INTERLEUKIN-5 THERAPY, MEPOLIZUMAB, IN CHRONIC EOSINOPHILIC PNEUMONIA
    Lam, W.
    Ramsey, A.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2016, 117 (05) : S68 - S68
  • [49] Anti-IL-5 therapy in patients with severe eosinophilic asthma – clinical efficacy and possible criteria for treatment response
    Nora Drick
    Benjamin Seeliger
    Tobias Welte
    Jan Fuge
    Hendrik Suhling
    BMC Pulmonary Medicine, 18
  • [50] Anti-IL-5 therapy in patients with severe eosinophilic asthma - clinical efficacy and possible criteria for treatment response
    Drick, Nora
    Seeliger, Benjamin
    Welte, Tobias
    Fuge, Jan
    Suhling, Hendrik
    BMC PULMONARY MEDICINE, 2018, 18
12345